Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02185690
Title A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University Health Network, Toronto, Novartis
Indications

lung large cell carcinoma

lung adenocarcinoma

Therapies

Binimetinib + Carboplatin + Pemetrexed Disodium

Age Groups: adult | senior
Covered Countries CAN

Additional content available in CKB BOOST